drugset / Trial / NCT00839917
A Study of ProQuad™ in Healthy Children in Korea (V221-023)
RandomizedParallel-groupOpen-labelPrevention
Summary
This study will compare ProQuad™ and concomitant administration of M-M-R™ II and Varivax™ with respect to immunogenicity, safety and tolerability. The primary hypothesis to be tested is that the antibody response rates to measles, mumps, rubella, and varicella 6 weeks after vaccination with ProQuad™ will be non-inferior to the antibody response rates after vaccination with concomitant M-M-R™ II and Varivax™.
Timeline
- Start
- 2008-02
- Primary completion
- 2008-05
- Completion
- 2008-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | M-M-R II | Vaccine | 0.5 ml | Subcutaneous |
| Subject | ProQuad | Vaccine | 0.5 ml | Subcutaneous |
| Comparator | Varivax | Vaccine | 0.5 ml | Subcutaneous |